Human factor V is activated to factor Va by alpha-thrombin after cleavages at Arg709, Arg1018, and Arg1545. Factor Va is inactivated by activated protein C (APC) in the presence of a membrane surface after three sequential cleavages of the heavy chain. Cleavage at Arg506 provides for efficient exposure of the inactivating cleavages at Arg306 and Arg679. Membrane-bound factor V is also inactivated by APC after cleavage at Arg306. Resistance to APC is associated with a single nucleotide change in the factor V gene (G1691-->A) corresponding to a single amino acid substitution in the factor V molecule: Arg506-->Gln (factor V Leiden). The consequence of this mutation is a delay in factor Va inactivation. Thus, the success of the APC-resistance assay is based on the fortuitous activation of factor V during the assay. Plasmas from normal individuals (1691 GG) and individuals homozygous for the factor V mutation (1691 AA) were diluted in a buffer containing 5 mmol/L CaCl2, phospholipid vesicles (10 micromol/L), and APC. APC, at concentrations < or = 5.5 nmol/L, prevented clot formation in normal plasma, whereas under similar conditions, a clot was observed in plasma from APC-resistant individuals. Gel electrophoresis analyses of factor V fragments showed that membrane-bound factor V is primarily cleaved at Arg306 in both plasmas. However, whereas in normal plasma production of factor Va heavy chain is counterbalanced by fast degradation after cleavage at Arg506/Arg306, in the APC-resistant individuals' plasma, early generation and accumulation of the heavy chain portion of factor Va occurs as a consequence of delayed cleavage at Arg306. At elevated APC concentrations (>5.5 nmol/L), no clot formation was observed in either plasma from normal or APC-resistant individuals. Our data show that resistance to APC in patients with the Arg506-->Gln mutation is due to the inefficient degradation (inactivation) of factor Va heavy chain by APC.
Skip Nav Destination
ARTICLES|
June 1, 1996
Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay
M Kalafatis,
M Kalafatis
Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405–0068, USA.
Search for other works by this author on:
PE Haley,
PE Haley
Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405–0068, USA.
Search for other works by this author on:
D Lu,
D Lu
Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405–0068, USA.
Search for other works by this author on:
RM Bertina,
RM Bertina
Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405–0068, USA.
Search for other works by this author on:
GL Long,
GL Long
Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405–0068, USA.
Search for other works by this author on:
KG Mann
KG Mann
Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405–0068, USA.
Search for other works by this author on:
Blood (1996) 87 (11): 4695–4707.
Citation
M Kalafatis, PE Haley, D Lu, RM Bertina, GL Long, KG Mann; Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood 1996; 87 (11): 4695–4707. doi: https://doi.org/10.1182/blood.V87.11.4695.bloodjournal87114695
Download citation file:
June 1 1996
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal